Cas:1598410-12-8 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] manufacturer & supplier

Chemical Name:4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene]

CAS.NO:1598410-12-8

Synonyms:4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene]

Molecular Formula:C₃₁H₂₀BrN

Molecular Weight:486.4012

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] Use and application,4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] technical grade,usp/ep/jp grade.

Related News: The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] manufacturer The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] supplier The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] vendor The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 4′-bromo-10-phenyl-10H-spiro[acridine-9,9′-fluorene] factory The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.